Schlappack O K, Peacock J H, Haslinger R K, Schmidt W F, Eady J J
Radiotherapy Research Unit, Institute of Cancer Research Sutton, Surrey, U.K.
Strahlenther Onkol. 1988 Nov;164(11):684-8.
MTDQ, and its watersoluble derivative MTDQ-DA, have been tested in combination with radiation using the murine plasmacytoma X5563 and the Lewis lung carcinoma. Neither of the two compounds showed any effect on the single dose radiation response as measured by tumour growth delay. In addition no effect of MTDQ-DA on the response of the X5563 plasmacytoma to fractionated radiation was observed. As a control, studies with the established hypoxic cell sensitizer Misonidazole showed that both tumours could be sensitized to radiation by that drug, in the case of Lewis lung carcinoma the use of the excision cell survival assay showed that this was due to hypoxic cell sensitization.
已使用小鼠浆细胞瘤X5563和Lewis肺癌对MTDQ及其水溶性衍生物MTDQ-DA与辐射联合进行了测试。通过肿瘤生长延迟测量，这两种化合物对单剂量辐射反应均未显示出任何影响。此外，未观察到MTDQ-DA对X5563浆细胞瘤对分次辐射反应的影响。作为对照，对已确立的乏氧细胞增敏剂米索硝唑的研究表明，该药物可使两种肿瘤对辐射敏感，就Lewis肺癌而言，使用切除细胞存活试验表明这是由于乏氧细胞增敏所致。
